Latest Comments

ESMO 2017: An uncertain future for Merck’s Keytruda

ESMO 2017: An uncertain future for Merck’s Keytruda

An update on PARP inhibitors: ovarian cancer and beyond

An update on PARP inhibitors: ovarian cancer and beyond

Ten-year old NICE restrictions on Velcade limit patient access to next-gen therapies

Ten-year old NICE restrictions on Velcade limit patient access to next-gen therapies

Array BioPharma’s BRAF/MEK combination set for approval review in Europe

Array BioPharma’s BRAF/MEK combination set for approval review in Europe

FDA rejection of Acorda’s Inbrija is another challenge after Ampyra patent setback

FDA rejection of Acorda’s Inbrija is another challenge after Ampyra patent setback

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

Despite Humira patent expiry, Abbvie is poised to remain a market leader in Crohn’s disease

Despite Humira patent expiry, Abbvie is poised to remain a market leader in Crohn’s disease

The future of vaccines – could they really grow on trees?

The future of vaccines – could they really grow on trees?

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

Anti-nerve growth factor antibodies expected to drive osteoarthritis market growth

Anti-nerve growth factor antibodies expected to drive osteoarthritis market growth

BMS shifts towards precision medicine

BMS shifts towards precision medicine

pSivida and Alimera enter new phase of collaboration on the longest-acting ocular steroid implant

pSivida and Alimera enter new phase of collaboration on the longest-acting ocular steroid implant

Dynavax’s Heplisav-B passes key regulatory hurdle with FDA Advisory Committee endorsement

Dynavax’s Heplisav-B passes key regulatory hurdle with FDA Advisory Committee endorsement

Fighting obesity: Past and future treatments

Fighting obesity: Past and future treatments

Breakthroughs for orphan designated hematological drugs could earn big revenues

Breakthroughs for orphan designated hematological drugs could earn big revenues

A vaccine for Lyme disease – second time lucky?

A vaccine for Lyme disease – second time lucky?

Strong safety and efficacy data position Aerie Pharmaceuticals to submit glaucoma NDA for Roclatan

Strong safety and efficacy data position Aerie Pharmaceuticals to submit glaucoma NDA for Roclatan

NICE: too nice for too long?

NICE: too nice for too long?

Will lampalizumab finally provide a treatment for macular degeneration?

Will lampalizumab finally provide a treatment for macular degeneration?

Gilead looks to maintain dominance in HIV with its novel STR

Gilead looks to maintain dominance in HIV with its novel STR